Month: May 2020

Prosafe SE will release its first quarter 2020 results on 27 May 2020 at approx. 07:00 a.m. CEST. The Q1 2020 report and the Q1 2020 presentation will be published on www.newsweb.no and on Prosafe’s website www.prosafe.com

(Oslo, 14 May 2020) Saga Tankers ASA (“Saga”, OSE: SAGA) reported a net asset value (NAV) of NOK  251 million end of the first quarter 2020, corresponding to NOK 0.94 per outstanding share, excluding minority interests and with Vallhall valued at book value.By the end of the first quarter, Saga had a cash balance of NOK 113 million. All long-term debt are related to the real estate owned by Vallhall (Saga’s ownership is 55%).During the quarter, the net market value of shares held in SD Standard Drilling Plc and Vistin Pharma ASA decreased by approx. NOK 85 million. This is classified as net loss from available for sale assets.Saga has not made any adjustments in the portfolio classified as financial assets available for sale during the quarter.Key figuresFinancial assets are adjusted to market value according to IFRS. Vallhall Arena is...

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rateData confirm previous preliminary efficacy data seen in this subpopulationMARSEILLE, France, May 14, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present new data on its lead partnered asset, monalizumab, at the ASCO20 Virtual Scientific Program being held May 29-31, 2020. The presentation will highlight a Phase II expansion cohort investigating the combination of monalizumab and cetuximab in patients with recurrent or metastatic head and neck squamous cell cancer (R/M SCCHN) who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors (“IO-pretreated”). Monalizumab is a potentially first-in-class immune...

            – Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year –             –  Enrollment paused in ongoing trials under Janssen and LEO Pharma collaborations  –                         – ARGX-117 being evaluated in COVID-19 patients with acute respiratory distress syndrome in collaboration with UZ Gent –            – Management to host conference call today at 3:00 pm CEST (9:00 am ET) –May 14, 2020Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its financial...

May 14, 2020HighlightsResponding to COVID-19 challenges to safeguard health and safety of staff and protect our assetsEnsuring continuous operation of projects and fleet (uptime of 99.3%) in the current environmentCost reduction to mitigate COVID-19 impacts and adapt to market circumstancesYear-to-date Directional1­­­­­revenue of US$607 million, in line with expectation2020 Directional revenue guidance adjusted from “above” to “around” US$2.3 billion2020 Directional EBITDA guidance maintained at around US$900 millionFinal modules for the Johan Castberg Turret Mooring System shippedUS$150 million dividend paid and EUR150 million 2020 share repurchase program completedBruno Chabas, CEO of SBM Offshore, commented:“SBM Offshore delivered a good set of results during the first quarter of 2020, in line with expectations. The Company’s results,...

Oslo, 14 May 2020 – Adevinta ASA has on 13 May 2020 purchased 25,000 own shares at an average price of NOK 98.4041 per share. After this, Adevinta ASA owns a total of 25,000 own shares.The purchase of shares is a result of the company’s decision announced on 13 May 2020 of up to 320,000 shares. The shares are to be used as settlement in the Company’s share-based incentive schemes as well as employee share saving plans.This information is subject to disclosure requirements pursuant to §4-2 and §5-12 of the Norwegian Securities Trading Act. 

FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease*Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)PARIS – May 14, 2020 – The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi’s Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s.If approved, sutimlimab would be the first and only approved treatment for these patients. The target action date for the FDA decision is November 13, 2020. CAD is a chronic autoimmune hemolytic anemia that causes the body’s immune system to mistakenly...

La FDA accorde un examen prioritaire au sutimlimab, premier et seul traitement potentiel de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides*Le sutimlimab cible l’hémolyse déclenchée par l’activation du C1 dans la maladie des agglutinines froides (MAF)PARIS – Le 14 mai 2020 – La Food and Drug Administration (FDA) des États-Unis [a accordé un examen prioritaire à la demande de licence de produit biologique (Biologics License Application, BLA) de Sanofi relative au sutimlimab pour le traitement de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides (MAF). Le sutimlimab, un anticorps monoclonal expérimental, cible la cause sous-jacente de l’hémolyse dans la MAF en inhibant sélectivement le complément C1s.S’il est approuvé, le sutimlimab sera le premier et le seul traitement approuvé pour cette...

Operational The fleet utilisation rate in the first quarter of 2020 was 32.7 per cent (Q1 2019: 62.5 per cent).  Prosafe refers to the press release from the March 2020 regarding discussions with clients about current and upcoming contracts in light of COVID-19 and the oil price collapse. These discussions are ongoing. Please see status and update per vessel below.